astx727,modakafusp alfa
takeda,astex pharmaceuticals,immunogen
['modakafusp', 'tak-573', '573', 'mmsm', 'multiplemyeloma', 'immunogen']
nct03215030: phase 1/2: safety, tolerability, efficacy, pharmacok. immunogenicity of tak-573 in rrmm
modakafusp alfa (tak-573) #mmsm #multiplemyeloma #eha2022 
Multiple Myeloma Education Platform for Myeloma Community